A New Hope for Little Hearts: FDA Greenlights Pediatric VAD Trial

BURLINGTON, Mass. – April 24, 2026 – BrioHealth Solutions has received conditional approval from the U.S. Food and Drug Administration (FDA) to begin a clinical trial for its BrioVAD® System, a miniaturized heart pump, in children with advanced heart failure. This pivotal study, named the Brio4Kids Trial, represents a significant step toward addressing a critical gap in medical technology for one of the most vulnerable patient populations and offers a new lifeline to children whose hearts are failing.

The trial will be conducted under the existing Investigational Device Exemption (IDE) for the company's adult study, the INNOVATE Trial, signaling a streamlined regulatory path for a device aimed at an area of profound unmet need.

The Urgent Need for Child-Sized Solutions

Advanced heart failure in children, while less common than in adults, is a devastating condition with limited long-term treatment options. Caused by a range of issues from congenital heart defects to cardiomyopathy, it leaves young patients in a precarious state, often tethered to hospitals while awaiting a heart transplant. According to data from the Advanced Cardiac Therapies Improving Outcomes Network (ACTION), the use of ventricular assist devices (VADs) in pediatric patients has surged, rising from 26% in 2018 to 42% in 2023, highlighting a growing reliance on mechanical support for children with refractory heart failure.

However, the available technology has struggled to keep pace. For years, clinicians have faced a difficult choice: use VADs designed and approved for adults in an off-label capacity for larger children, risking a mismatch between the patient's body and the device, or rely on existing pediatric-specific devices. The most widely used of these, the Berlin Heart EXCOR, is an extracorporeal pump, meaning its main components remain outside the body. While life-saving, this design severely restricts a child's mobility and quality of life, effectively confining them to a hospital setting.

This is the gap BrioHealth aims to fill. "In pediatric heart failure, including in school-age children, the lack of durable LVAD options remains a major challenge," commented Dr. Angela Lorts, a Professor of Heart Failure at Cincinnati Children's Hospital Medical Center and a national principal investigator for the study. "This represents a significant unmet need, and we are encouraged to explore the potential of the BrioVAD System through the Brio4Kids study."

Engineering a Lifeline: The BrioVAD System

The BrioVAD System is not merely a smaller version of an adult device; it has been engineered from the ground up with features specifically intended to benefit smaller patients. Its core is a compact, fully magnetically levitated pump that is approximately 20% smaller than Abbott's market-leading HeartMate 3. This reduced size could allow for implantation in a wider range of pediatric patients and potentially lead to less invasive surgical procedures.

Beyond the pump itself, the system incorporates a novel, significantly thinner and more flexible driveline—the external cable that connects the internal pump to the external power source. This design innovation directly targets one of the most persistent and dangerous complications of VAD therapy: driveline-associated infections. By creating a better interface with the skin, the company hopes to reduce this risk. The external components worn by the patient are also designed to be lightweight and minimal, a crucial factor for improving the quality of life and freedom of movement for a child.

Underpinning this design is a focus on hemocompatibility. The magnetically levitated rotor is engineered to create a low-turbulence blood flow path, which helps minimize damage to blood cells as they pass through the pump. While the Brio4Kids trial will be the first formal evaluation in U.S. children, the pump technology is not entirely new to the clinical setting. A version of the device, known as the CH-VAD in China, has already been implanted in over 350 patients outside the United States, providing a substantial foundation of real-world data and clinical experience.

Charting a Complex Regulatory Course

Bringing any new medical device to the pediatric market is a formidable challenge, fraught with ethical considerations, small patient populations, and high regulatory hurdles. The FDA's decision to grant conditional approval for the Brio4Kids trial to proceed under the existing IDE of the adult INNOVATE trial is a noteworthy development. It suggests a degree of confidence in the device's foundational technology and may help accelerate the evaluation process.

The INNOVATE trial itself is an ambitious undertaking, designed as a head-to-head, non-inferiority study comparing the BrioVAD directly against the HeartMate 3 in adults. Having already enrolled its first 100 patients and received FDA approval to proceed to its pivotal phase, the adult trial's progress has likely bolstered the case for the pediatric study. Enrollment for the Brio4Kids trial is expected to begin in mid-2026, with the first look at initial data anticipated in the fourth quarter of the same year.

This approach allows BrioHealth to leverage its existing clinical and regulatory infrastructure, a critical advantage in the high-cost, high-risk world of medical device development. It also places the BrioVAD on a path that could eventually provide a durable, implantable option for children, a stark contrast to the bridge-to-transplant designation held by many current pediatric support devices.

A Strategic Move in a Competitive Field

The launch of the Brio4Kids trial is also a calculated strategic maneuver in the multi-billion-dollar ventricular assist device market. The field is currently dominated by a few key players. Abbott's HeartMate 3 holds a commanding share of the adult market, while Berlin Heart is the established specialist in the niche pediatric space. With its two major clinical trials, BrioHealth is positioning itself to challenge both.

The INNOVATE trial represents a direct bid to compete with Abbott in the larger adult market, while the Brio4Kids trial targets a specific, underserved segment where a technologically advanced, fully implantable device could become the new standard of care. Success in the pediatric space could not only provide a crucial new therapy but also build significant brand and clinical trust for the BrioVAD platform as a whole.

For BrioHealth Solutions, which has operations across the U.S., China, and Europe, this marks a pivotal moment. "This is another important milestone in our journey to becoming a global leader in innovation and delivering best-in-class service in our field," said Chen Chen, Ph.D., CEO of BrioHealth Solutions. As the company prepares to enroll the first young patients in this landmark study, the hopes of families and physicians for a more durable and liberating solution for pediatric heart failure will be watching closely.